Karsten Henco

DIB Doblinger Industriebeteiligung GmbH & Co. Holding KG is a private equity firm. The company is based in Munich, Germany.

Medovent GmbH engages in the development and manufacture of medical devices made of the biopolymer chitosan. Its main products are a nerve guide used for peripheral nerve injuries and a direct suture for short nerve defects. The company was founded by Rivelino Montenegro and Thomas Freier in 2006 and is headquartered in Mainz, Germany.

ETHRIS GmbH is a German company that specializes in developing innovative therapies and vaccines using its proprietary messenger RNA technology platform. The company is based in Planegg, Germany. The company is a leader in delivering stabilized mRNA directly to the respiratory system via optimized formulation and nebulization technologies. ETHRIS is rapidly advancing its pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. The company was founded by Carsten Rudolph and Christian Plank, and Carsten Rudolph has been the CEO since incorporation.

QIAGEN GmbH provides products for preanalytical sample preparation and molecular diagnostics solutions. It develops and markets consumable products and automated solutions to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. The company was founded in 1984 and is headquartered in Hilden, Germany.

Qiagen SRL is engaged in providing assay technologies. The company is headquartered in Milan, Italy.

U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany.